Pharmacologic treatments for covid-19 patients
Analyses are updated every Friday
Treatment comparisons
Create and download your forest plots with the most up-to-date data here Forest plots
Display new or updated analyses
Your research: comparisons updated with new studies
Access the forest plots for the 2 treatment comparisons .
Monoclonal antibodies (2 comparisons)
General characteristics of primary studies
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| NCT04412772 ARCHITECTS, Unpublished, 2021 |
Public/non profit | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (critical) admitted to a single center in the USA. | N=21 |
Low Details |
|
| NCT04324073 CORIMUNO-SARI, Unpublished, 2021 |
Public/non profit | Standard care | Sarilumab | RCT | Patients with suspected or confirmed COVID-19 (moderate-severe) admitted to multiple centers in France. | N=* |
Low Details |
|
| NCT04331808 CORIMUNO-TOCI-2 (ICU), Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. | N=* |
Low Details |
|
| NCT04330638 COV-AID, Unpublished, 2021 |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to 16 centers in Belgium | N=153 |
Low Details |
|
| NCT04479358 COVIDOSE-2, Unpublished, 2021 |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to multiple centers in the USA | N=28 |
Low Details |
|
| NCT04577534 COVIDSTORM, Unpublished, 2021 |
Not reported/unclear | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe) admitted to a single center in Finland. | N=39 |
Low Details |
|
| NCT04435717 COVITOZ-01, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with suspected or confirmed COVID-19 (mild-moderate-severe) admitted to a single center in Spain. | N=26 |
Low Details |
|
| NCT02735707 Derde L, REMAP-CAP, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate to critical) admitted to 133 centers in 9 countries | N=2253 |
Some concerns Details |
|
| Sarilumab | Standard care | |||||||
| Anakinra | Standard care | |||||||
| NCT02735707 Gordon AC, REMAP-CAP, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed or suspected COVID-19 (severe-critical) admitted to 113 centers in Australia, Ireland, the Netherlands, New Zealand, Saudi Arabia, UK. | N=826 |
Some concerns Details |
|
| Sarilumab | Standard care | |||||||
| NCT04331808 Hermine O, JAMA Intern Med, 2020 Full text Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with COVID-19 (moderate-severe) admitted to nine centers in France | N=131 |
Some concerns Details |
|
| NCT04377750 HMO-0224-20, Unpublished, 2021 |
Public/non profit | Placebo | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to multiple centers in Israel. | N=54 |
High Details |
|
| NCT04381936, ISRCTN50189673 Horby P, Lancet, 2021 Full text Commentary Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (moderate-critical) admitted to 131 centers in the UK | N=4116 |
Some concerns Details |
|
| NCT04412291, EudraCT 2020-001748-24 IMMCOVA, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a multiple centerd in Sweden | N=49 |
Low Details |
|
| NCT04327388; EudraCT2020-001162-12; U1111-1249-602 Lescure FX, 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 45 centers in Argentina, Brazil, Canada, Chile, France, Germany, Israel, Italy, Japan, Russia, and Spain. | N=420 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| NCT04409262 REMDACTA, Unpublished, 2021 |
Private | Placebo | Tocilizumab | RCT | Patients with confirmed COVID-19 (severe-critical) admitted to a multiple centers in Spain, USA, Brazil and Russia. | N=640 |
Some concerns Details |
|
| NCT04320615 Rosas I, N Engl J Med, 2021 Full text Commentary |
Mixed | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (mild-critical) admitted to multiple centers across 9 countries | N=452 |
Low Details |
|
| Trial NL8504 Rutgers A, SSRN, 2021 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 11 centers in the Netherlands. | N=354 |
Some concerns Details |
|
| NCT04372186 Salama C, N Engl J Med, 2020 Full text Full text Commentary Commentary |
Private | Tocilizumab | Placebo | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to 65 centers in Brazil, Kenya, Mexico, Peru, South Africa, and USA | N=388 |
Some concerns Details |
|
| NCT04346355 Salvarani C, JAMA , 2020 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (severe) admitted to 24 centers in Italy | N=126 |
Some concerns Details |
|
| NCT04357808 SARCOVID, Unpublished, 2021 |
Mixed | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (mild-severe) admitted to a single center in Spain. | N=30 |
Low Details |
|
| NCT04357860, EU-CTR 2020-001531-27 SARICOR, Unpublished, 2021 |
Public/non profit | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate) admitted to 10 centers in Spain | N=115 |
Low Details |
|
| EU-CTR 2020-002037-15 SARTRE, Unpublished, 2021 |
Private | Sarilumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 5 centers in Spain | N=140 |
Low Details |
|
| NCT04315298 Sivapalasingam S (1), 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 56 centers in the USA | N=457 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| NCT04315298 Sivapalasingam S (2), 2021 Full text Commentary Commentary |
Private | Sarilumab 400mg | Placebo | RCT | Patients with confirmed COVID-19 (moderate-severe-critical) admitted to 56 centers in the USA | N=1330 |
Some concerns Details |
|
| Sarilumab 200mg | Placebo | |||||||
| Sarilumab 400mg | Sarilumab 200mg | |||||||
| CTRI/2020/05/025369 Soin AS, Lancet Respir Med, 2021 Full text Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 12 centers in India | N=180 |
Some concerns Details |
|
| NCT04356937 Stone JH, N Engl J Med, 2020 Full text Commentary |
Private | Tocilizumab | Placebo | RCT | Patients with COVID-19 (mild-severe) admitted to seven centers in USA | N=243 |
Low Details |
|
| IRCT20081027001411N4 Talaschian M, Research Square, 2021 Full text Commentary Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to a single center in Iran | N=40 |
High Details |
|
| NCT04332094, EudraCT 2020-001442-19 TOCOVID, Unpublished, 2021 |
Public/non profit | Standard care | Tocilizumab | RCT | Patients with confirmed COVID-19(mild-moderate) admitted to multiple centers in Spain. | N=270 |
Low Details |
|
| NCT04324073 Unpublished, 2021 |
Public/non profit | Sarilumab | Standard care | RCT | Patients with suspected or confirmed COVID-19 (severe-critical) admitted to multiple centers in France. | N=* |
Some concerns Details |
|
| NCT04403685 Veiga VC, BMJ, 2021 Full text Commentary Commentary |
Mixed | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-critical) admitted to 9 centers in Brazil | N=129 |
Some concerns Details |
|
| ChiCTR2000029765 Wang D, Front Med, 2021 Full text Full text Commentary |
Public/non profit | Tocilizumab | Standard care | RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 6 centers in China | N=65 |
Some concerns Details |
|